BridgeBio Pharma Inc vs Gold Fields Limited — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Gold Fields Limited trades at $41.47 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 2.2× BridgeBio Pharma Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GFI | |
|---|---|---|
Market Cap | $16.36B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $61.52 |
52-Week Low | $47.29 | $29.31 |
Enterprise Value | $18.14B | $37.51B |
Dividend Yield | — | 5.76% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →